Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.

Claassen, Daniel O; Carroll, Benjamin; De Boer, Lisa M; Wu, Eric; Ayyagari, Rajeev; Gandhi, Sanjay; Stamler, David

Claassen, Daniel O; Carroll, Benjamin; De Boer, Lisa M; Wu, Eric; Ayyagari, Rajeev; Gandhi, Sanjay; Stamler, David.

Afiliação

Claassen DO; Vanderbilt University, 1161 21st Avenue South A-0118, Nashville, TN 37232 USA.
Carroll B; Teva Pharmaceuticals, Frazer, PA USA.
De Boer LM; Teva Pharmaceuticals, La Jolla, CA USA.
Wu E; Analysis Group, Inc., Boston, MA USA.
Ayyagari R; Analysis Group, Inc., Boston, MA USA.
Gandhi S; Teva Pharmaceuticals, Frazer, PA USA.
Stamler D; Teva Pharmaceuticals, La Jolla, CA USA.

J Clin Mov Disord ; 4: 3, 2017.

Article em En | MEDLINE | ID: mdl-28265459

Palavras-chave

Chorea; Deutetrabenazine; Huntington disease; Huntington's chorea; Indirect treatment comparison; Movement disorders; Risk difference; Safety; Tetrabenazine; Tolerability

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article